Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Gains Rights to Provide Pathology's Miscarriage Tests

NEW YORK (GenomeWeb News) – CombiMatrix said today that Pathology has chosen it to serve as the exclusive provider of Pathology's chromosomal microarray tests for the products of conception testing market in the US.

The deal expands an earlier strategic partnership between the firms forged late last year that provided Pathology with the right to market and distribute CombiMatrix's microarray tests in California and Nevada, as well as St. Louis and Chicago. Products of conception testing is also called miscarriage testing and is a subset of the prenatal testing market.

"We believe this market is going to continue to expand as our physician customers and their patients realize the importance of microarray testing in helping to identify the causes of miscarriages and how that information may assist in future pregnancies," Pathology President and CEO Vicki DiFrancesco said in a statement.

CombiMatrix President and CEO Mark McDonough added that the expansion of the firms' earlier deal "underscores the rapidly expanding importance of microarray testing and the value our team brings to Pathology in terms of operational and analytical support." He said that the deal with Pathology "allows us to extend our customer base of Ob/Gyns and provides us with additional marketing and distribution support."

Financial and other terms were not disclosed.